Scienture Holdings, Inc.

Scienture Holdings, Inc. is a publicly traded pharmaceutical holding company that focuses on developing, bringing to market, and distributing novel specialty products to address unmet market needs. The company's mission is to provide enhanced value to patients, physicians, and caregivers through its pharmaceutical operating companies. Headquartered in Tampa, Florida, Scienture Holdings, Inc. aims to improve health outcomes through innovation and strategic commercialization.

The company's key product offerings include Arbli™ (losartan potassium) oral suspension, the first FDA-approved oral liquid formulation of losartan for cardiovascular use, and REZENOPY™ (naloxone HCl) nasal spray, which is the highest-dose FDA-approved naloxone nasal spray on the U.S. market. Scienture Holdings primarily targets the Central Nervous System (CNS) and Cardiovascular (CVS) disease areas, with a pipeline that includes candidates like SCN-104, SCN-106, and SCN-107.

In recent news, Scienture Holdings, Inc. received a 180-day extension from Nasdaq in April 2026 to regain compliance with the minimum bid price requirement. The company reported a 216% revenue growth in 2025 and secured an $11.42 million secured notes financing agreement in April 2026. Leadership transitioned in May 2025, with Shankar Hariharan, Ph.D., serving as Executive Chairman and Co-CEO, and Narasimhan Mani, Ph.D., MBA, as President and Co-CEO. The company also divested its legacy Healthcare IT and Wholesale Operations subsidiaries in April 2025 to sharpen its focus on the Branded and Specialty Pharma segment.